Synthesis of Homoaristeromycin Analogues as Potent antiviral agents by 신영섭
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()-Aristeromycin (1) exhibits significant antiviral activity through inhibition of S-
adenosylhomocysteine (SAH) hydrolase, which has been a promising target for many 
broad antiviral agents. However, its therapeutic utility has been limited due to its the 
significant toxicity. This cytotoxicity arise from 5'-phosphorylation to the corresponding 
nucleotides by cellular kinase. To lower cytotoxicity, an approach of extending the C-5' 
hydroxymethyl side chain by one carbon homologation was made to provide the C-5' 
homolog of ()-aristeromycin. Furthermore, we thought that introduction of fluorine atom 
at 6'-position which is bioisostere with hydrogen atom improves antiviral activity by SAH 
hydrolase inhibitory effect. 
 Based on these strategy, 6'-fluoro-homoaristeromycin analogues were designed and 
synthesized via Michael reaction and stereoselective electrophilic fluorination as key steps. 
(‒)-6'--Fluoro-homoaristeromycin (3) showed potent inhibition of SAH hydrolase (IC50 = 
0.36 nM), high anti-Chikungunya activity (EC50 = 0.12 M) and low cytotoxicity (CC50 > 
250 M). Selectivity index is more than 2087. 
In brief, the (‒)-6'--fluoro-homoaristeromycin (3) showed potent activity against 
Chikungunya virus and low toxicity. This study can be extensively applied to the 
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Nucleosides are fundamental elements in all living systems and building blocks of nucleic 
acids. Modified nucleosides have been playing major role in fighting tumors and viruses, 
either as selective inhibitors of certain necessary enzymes for cancer or viral reproduction 
or as nucleic acid chain terminators that interrupt the replication of cancer cells or a virus.1 
 The carbocyclic nucleosides, in which the furanose oxygen has been replaced by 
methylene group, have the inherent strength that they are not subject to the action of 
nucleoside phosphorylases and hydrolases that cleave normal nucleosides.2 
 
 
Figure 1. Gradual evolution of a nucleoside. 
 
The adenosine analogue, ()-aristeromycin is isolated from Streptomyces citricolor and 
the representative of naturally occurring carbocyclic nucleosides. ()-Aristeromycin 
exhibits both significant antiviral and antitumor activity.3,4 
 This compound shows as potent activity against S-adenosylhomocysteine (SAH) 
hydrolase, which is an enzyme responsible for the hydrolysis of S-adenosylhomocysteine 
(SAH) into adenosine and L-homocysteine. SAH is a strong feedback inhibitor of a 
methyltransferase enzyme that involves S-adenosyl-L-methionine (SAM), which results in 
inhibition of biological methylation of viral RNA. Therefore, inhibition of SAH hydrolase 







Figure 2. Structure of ()-aristeromycin (1) 
 
As a number of viruses are sensitive to SAH hydrolase inhibitors, the inhibitors show a 
broad antiviral activity spectrum. Members of the Poxviridae and Rhabdoviridae are 
exquisitely sensitive to SAH hydrolase inhibitors. In addition, SAH hydrolase inhibitors 
were shown to be effective against human immunodeficiency virus (HIV) but only under 
specific test conditions (optimized for minimizing cytotoxicity). However, the (+)-RNA 
viruses other than retroviruses (HIV) are virtually insensitive to SAH hydrolase inhibitors.6 
 Thus, SAH hydrolase has been recognized for a long time as a potential target for 
antiviral chemotherapy and several carbocyclic nucleosides7 were found to exert their 
antiviral action through inhibition of SAH hydrolase. 
 






Though ()-aristeromycin is a potent SAH hydrolase inhibitor, its therapeutic utility has 
been limited, because of the significant toxicity. This cytotoxicity arise from through 5'-
phosphorylation of the corresponding nucleotides by cellular kinase. Therefore, 
modifications based on ()-aristeromycin have generated a series of carbocyclic analogues 
that retain the inhibitory activity toward SAH hydrolase, while being devoid of the 
toxicity.4 
 Our group designed fluorinated homoaristeromycin to lower cytotoxicity and improve 
activity against viruses. First of all, an approach is extension of the C-5' hydroxymethyl 
side chain by one carbon homologation to provide the C-5' homolog of ()-aristeromycin. 
This analog can be expected to have displaced the phosphate-susceptible hydroxyl from 
the phosphate-transfer zone in the kinases. In support of this, ()-homoaristeromycin 2 has 
been reported to be inactive against HSV-1 and HSV-2, possibly, due to its failure to be 
phosphorylated.8 Furthermore, we thought that introduction of fluorine which is bioisostere 











Herein, we designed and synthesized enantiomerically pure 6'-fluoroaristeromycin. We 
envisaged that we could stereoselective synthesize and examine the biological activities for 
the fluorinated aristeromycin analogues. This could be achieved from an inexpensive 




II. Results and Discussion 
 
For many years, our laboratory has researched for our continuing interest in the 
development of several types of carbocyclic nucleosides.10,11 Therefore, we have gained 
substantial insights toward the synthesis of glycosyl donors from a relatively inexpensive 










As shown in our retrosynthetic plans (Scheme 1), our strategy would utilize the linear 
purine and pyrimidine base build-up approach from amino intermediate 9 and 10, which 
could easily be derived from 11 and 12. It was envisaged that the -fluoroketone 11 could 
be synthesized through a stereoselective electrophilic fluorination of silyl enol ether, which 
could be easily accessed from compound 13. Di-fluorinated compound 12 could be also 
synthesized through same procedure from the -fluoroketone 11. Compound 19 could be 
synthesized from D-cyclopentenone 14 by a Michael reaction and the intermediate 14 could 
be efficiently derived from D-ribose with our previously published procedure12. 
To begin our synthesis (Scheme 2), D-ribose was converted to known 14 in five steps, 
according to a modified known procedure12 using ring-closing metathesis of 18 with 
Neolyst M2, followed by PDC oxidation. 
 
Reagents and conditions: (a) acetone, c-H2SO4, rt, 3 h; (b) vinylMgBr, THF, 78 °C to 
0 °C, 3 h; (c) NaIO4, H2O, 0 °C to rt, 40 min; d) NaH, DMSO, CH3PPh3Br, THF, 0 °C to 
reflux, 15 h; (e) (i) Neolyst M2, CH2Cl2, rt, 2 d; (ii) PDC, CH2Cl2, rt, 6 h. 
 






Reagent and Conditions: (a) vinylMgBr, CuBr·CH3SCH3, TMSCl, HMPA, THF, 78 °C, 
2 h; (b) NaBH4, MeOH, 0 °C, 1 h; (c) TBDPSCl, imidazole, DMF, 0 °C to rt, 3 h; (d) (i) 
BH3·CH3SCH3, THF, 0 °C to rt, 1 h; (ii) NaBO3·H2O, H2O, 0 °C to rt, 16 h; (e) TBAF, 
THF, 0 °C to rt, 16 h; (f) Et3N, DMAP, TBDPSCl (1.2 eq.), CH2Cl2, 0 °C to rt, 2 h; (g) 
NMO, 4 Å molecular sieves, TPAP, CH2Cl2, rt, 1 h. 
 
Scheme 3. Synthesis of the ketone intermediate 13. 
 
Michael addition of vinyl Grignard on 14 afforded known compound 1913 in 76% yield. 
The reduction of 1,4-addition product 19 using sodium borohydride gave the alpha alcohol 
20, since the concave region is hindered by the 2,3-isopropylidene ring group. The alcohol 
20 was protected with TBDPSCl, followed by hydroboration oxidation with borane-
dimethyl sulfide complex to give the hydroboration product 22. The deprotection of 





protection of primary hydroxyl group by 1.2 equivalent of TBDPSCl to afford compound 
24. The oxidation of compound 24 in the presence of tetrapropylammonium perruthenate 
and N-methylmorpholine N-oxide gave the ketone 13. 
 
 
Reagent and Conditions: (a) (i) TESCl, LiHMDS, THF, 78 °C, 1 h; (ii) selectfluor, 
CH3CN, 0 °C, 16 h; (b) (i) TESCl, LiHMDS, THF, 78 °C, 1 h; (ii) selectfluor, CH3CN, 
0 °C, 16 h; (c) NaBH4, THF, 40 °C to 0 °C, 3 h; (d) NaBH4, THF, 0 °C, 3 h; (e) (i) 
Tf2O, pyridine, 0 °C, 1 h; (ii) NaN3, DMF, 100 °C (for 27) or 60 °C (for 28), 12 h; (f) H2, 
Pd/C, MeOH, rt, 3 h (for 9) or 12 h (for 10). 
 
Scheme 4. Synthesis of the amine intermediate 9 and 10. 
 
The ketone 13 was then treated with chlorotriethylsilane and lithium 
bis(trimethylsilyl)amide to give silyl enol ether. The silyl enol ether was treated with 
selectfluor (1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane ditetrafluoroborate) 
which is as a conventional source of electrophilic fluorine to give the desired -fluoro-
cyclopentanone 11. The carbanion formed at C6 attacks electrophilic fluorine, which 





hindrance by the 2,3-isopropylidene ring. The di-fluorinated compound 12 was also 
synthesized from 11 by using same procedure in 50% yield. 
With the desired fluorinated sugar 11 in hand, our purpose was to synthesize fluorinated 
aristeromycin. . First of all, compound 11 and 12 were reduced with sodium borohydride 
to give alcohol 25 and 26, respectively, which were subjected to direct condensation 
reaction with the purine base under the Mitsunobu conditions. But, to our disappointment, 
Mitsunobu condensation failed. In addition, direct SN2 reactions (e.g. a mesylate or a triflate 
displacement of 25 and 26 with the in situ generated anion of the purine base) were 
unsuccessful. In contrast, the SN2 displacement of triflate with NaN3 occurred assumedly 
because the azide anion was a linear, less bulky and more powerful nucleophile. Compound 
27 and 28 were reduced to amine 9 and 10 respectively using palladium catalyst 10 wt. % 
on activated carbon under H2 atmosphere. 
The amine 9 was treated with 5-amino-4,6-dichloropyrimidine and triethylamine in n-
butanol under microwave irradiation to give 29. However, difluorinated amine 10 was 
decomposed in microwave. So, 4,6-dichloro-5-foramidopyrimidine was added to the 
difluorinated amine 10 at a reflux condition. As 4,6-dichloro-5-foramidopyrimidine was 
more stronger electrophile than 5-amino-4,6-dichloropyrimidine, compound 30 could be 
formed. Further, the cyclization of compound 29 and 30 using diethoxymethyl acetate gave 
the desired purine nucleoside 31 and 32 (Scheme 5). Interestingly, the 1H NMR spectrum 
of purine nucleoside 31 and 32 displayed doublet signals for the C8 position’s proton of 
purine base. This could arise from the long range coupling between the proton and the 
fluorine atom at C6' position, therefore, confirming the desired orientation of the fluorine 








Reagent and Conditions: (a) 5-amino-4,6-dichloropyrimidine (for 29) or 4,6-dichloro-5-
foramidopyrimidine (for 30), N,N-diisopropylethylamine, n-BuOH, MW, 170 °C, 10 h; (b) 
CH3C(O)OCH(OEt)2, 120 °C, 14 h; (c) 50% aq. TFA (for 33), 70% aq. TFA (for 34), 
MeOH, 0 °C to rt, 2 h; (d) NH3/t-BuOH, 90 °C, 3 h (for 3) or NH3/MeOH, 70 °C, 
overnight (for 7) or 40% aq. MeNH2, 80 °C, 5 h (for 4 and 8) or 1 N HCl, 1,4-dioxane, 
reflux, overnight (for 5). 
 
Scheme 5. Synthesis of the fluorinated homoaristeromycin analogues. 
 
Removal of the acetonide and TBDPS protecting groups of the nucleoside 31 and 32 by 
50% aqueous trifluoroacetic acid gave the nucleoside 33 and 34, respectively. For synthesis 
of the adenine nucleoside, saturated tert-butanolic ammonia (saturated methanolic 
ammonia solution for difluorinated compound 7) was added to the 6-chloropurine 





in steel bomb for synthesis of the N-methyl adenine nucleoside 4 and 8. The hypoxanthine 
5 was also synthesized in acidic condition through hydrolysis. The structure of 3 was 
confirmed by a single-crystal X-ray analysis (Figure 5). 
 
 
Figure 5. The crystal structure of 3 confirmed by X-ray crystallographic data analysis. 
 
Thus, our synthetic strategy led to an efficient synthesis of the fluorinated 
homoaristerommycin analogue in purine base. This gives new insights for development of 












Reagent and Conditions: (a) 2 M NaOH, 2 M HCl, rt, 2 h; (b) 2 M NaOH, rt, 5 min; (c) 
SOCl2, Et2O, reflux, 4 h; (d) AgNCO, C6H6, reflux, 30 min. 
 
 
In an attempt towards the synthesis of the pyrimidine analogue, we directly tried to 
construct the uracil base from the amine 9. We used commercially available methyl 3-
methoxy-2-propenoate 35 for the preparation of 3-methxoy-2-propenoyl isocyanate 39, 
which is suitable for formation of the uracil base. 
 
 
Scheme 5. Synthesis of 3-methoxy-2-propenoyl isocyanate 39.14 
 
Reagent and Conditions: (a) MeOCHCHCONCO, benzene, 4 Å molecular sieves, DMF, 
20 °C to rt, 15 h; (b) 2 M H2SO4, reflux, 30 min. 
 






Synthesis of isocyanate 39 began with hydrolysis of methyl 3-methoxy-2-propenoate 35 
at room temperature in basic condition. The resulting acid 36, as its sodium salt 37, was 
treated with thionyl chloride in dry ether, to afford the corresponding acid chloride 38, 
which was purified by vacuum distillation. Reaction of 38 with silver cyanate in benzene 
afforded the desired isocyanate 39, which was not isolated due to its known instability. 
Compound 9 in DMF was then treated with 3-methoxy-propenoyl isocyanate 39 along with 
molecular sieves at 20 °C and then gradually warmed to room temperature to obtain 
compound 40. This was immediately subjected to cyclization, followed by deprotection 



















3 0.36 >50 12.5 0.12 >250 >50 ND 
7 1.72 ND NA NA >25 NA ND 
*MERS-CoV: Middle East respiratory syndrome-related coronavirus 
 
Table 1. Results for the antiviral activity observed for compounds 3 and 7. 
 
The synthesized compound 3 and 7 were assayed for their antiviral activities against 
MERS-CoV, Chikungunya and Zika virus. Biological evaluation of the other compounds 
will be performed in the near future. As a result, -fluoro-homoaristeromycin 3 showed 
inhibition of SAH hydrolase and potent antiviral activity against Chikungunya virus 
without cytotoxicity. These results demonstrate that -fluoro-homoaristeromycin 3 may be 












Based on the structure of (‒)-aristeromycin, fluorinated homo-aristeromycin analogues 
were designed and synthesized from D-ribose via Michael reaction and stereoselective 
electrophilic fluorination as a key step. The -Fluoro-homoaristeromycin 3 showed potent 
anti-Chikungunya (EC50 = 0.12 µM) without cytotoxicity up to 250 µM, showing high 
selectivity index (CC50/EC50 > 2083). Compound 3 also exhibited potent inhibitory activity 
(IC50 = 1.72 μM) against SAH hydrolase. One carbon homologation of (‒)-aristeromycin 
might prevent 5'-phosphorylation, which resulted in a low cytotoxicity. Antiviral activity 
seems to be correlated with SAH hydrolase inhibitory activity. 





IV. Experimental Section 
 
1. General Procedure 
 
Proton (1H) and carbon (13C) NMR spectra were recorded on a Jeol JNMLA300 (300/75 
MHz), Bruker AV 400 (400/100 MHz), Bruker AMX 500 (500/125 MHz), Jeol JNM-
ECA600 (600/150 MHz), or Bruker AVANCE III 800 (800/200 MHz) spectrometer. 
Chemical shifts are reported in ppm units with Me4Si or NMR solvent as the internal 
standard. All reactions were routinely carried out under an inert atmosphere of dry nitrogen. 
Reactions were checked by thin layer chromatography (Kieselgel 60 F254, Merck). Spots 
were detected by viewing under a UV light, and by colorizing with charring after dipping 





organic solutions were dried over anhydrous magnesium sulfate and filtered prior to rotary 
evaporation at water pump pressure. The crude compounds were purified by column 
chromatography on a silica gel (Kieselgel 60, 70-230 mesh, Merck). Unless otherwise 
noted, materials were obtained from commercial suppliers and were used without 
purification. All solvents were purified and dried by standard techniques just before use. 
THF and Et2O were freshly distilled from sodium and benzophenone. Methylene chloride, 
toluene, and benzene were purified by refluxing with CaH2. Hexanes and ethyl acetate were 
purified by simple distillation. 
 
2. Experimental Procedures 
 




cyclopenta[d][1,3]dioxol-4-yl)oxy)diphenylsilane (21). To a stirred solution of 19 (8.2 g, 
45.0 mmol) in methanol (500 mL) was added sodium borohydride (2.2 g, 58.5 mmol) at 
0 °C and the reaction mixture was stirred at the same temperature for 1 h. The mixture was 
quenched with water (20 mL) and concentrated in vacuo. The residue was diluted with 
brine and extracted with ethyl acetate (3 × 300 mL). The combined organic layers were 
dried over anhydrous MgSO4, filtered and concentrated under reduced pressure to give the 
crude alcohol, which was used for the next reaction without further purification. To a stirred 
solution of crude alcohol 20 and imidazole (15.3 g, 224.5 mmol) in N,N-
dimethylformamide (240 mL) was added TBDPSCl (18.7 mL, 71.85 mmol) at 0 °C, under 
nitrogen atmosphere. The reaction mixture was stirred at room temperature for 3 h, 





combined organic layers were washed with water (5 × 200 mL), dried using anhydrous 
MgSO4 and concentrated in vacuo. The residue was purified by silica gel chromatography 
(hexanes:ethyl acetate = 99:1) to obtain 21 as colorless syrup (18.7 g, 99%):  –59.2 
(c 0.125, CH3OH); 1H NMR (400 MHz, CDCl3) δ 7.76 (m, 4H), 7.40 (m, 6H), 5.55 (ddd, J 
= 6.0, 10.4, 17.2 Hz, 1H), 4.85 (dt, J = 1.2, 9.2 Hz, 1H), 4.76 (dt, J = 2.0, 17.6 Hz, 1H), 
4.26 (m, 1H), 4.03 (m, 1H) 2.60 (m, 2H), 2.06 (m, 1H), 1.61 (m, 1H), 1.57 (s, 3H), 1.32 (s, 
3H), 1.09 (s, 9H); 13C NMR (100 MHz CDCl3) δ 138.6, 136.0, 129.7, 127.7, 114.7, 84.3, 
79.8, 73.4, 44.1, 34.7, 27.1, 26.5, 24.8, 19.4; HRMS (FAB) found 445.2165 [calcd for 
C26H34NaO3Si+ (M + Na)+ 445.2169]. 
 




cyclopenta[d][1,3]dioxol-4-yl)ethan-1-ol (22). To a stirred solution of 21 (1.72 g, 4.07 
mmol) in anhydrous tetrahydrofuran (35 mL) was carefully added borane-dimethyl sulfide 
complex (1.0 M solution in tetrahydrofuran, 8.95 mL, 8.95 mmol) at 0 °C. The reaction 
mixture was stirred at room temperature for 1 h and cooled to 0 °C, before sodium perborate 
(1.34 g, 13.43 mmol) and water (40 mL) were carefully added. The mixture was stirred at 
room temperature for 16 h, diluted with brine (10 mL) extracted with ethyl acetate (2 × 50 
mL). The combined organic layers were dried over anhydrous MgSO4, filtered and 
concentrated in vacuo. The residue was purified by silica gel column chromatography 
(hexanes:ethyl acetate = 4:1) to obtain 22 as colorless syrup (1.22 g, 71%):  –40.1 





2H), 4.18 (m, 1H), 4.05 (m, 1H), 3.53 (m, 1H), 1.99 (m, 1H) 1.55 (s, 3H), 1.35 (s, 3H), 
1.35 (m, 1 H), 1.32 (s, 3H), 1.26 (m, 1H), 1.09 (s, 9H); 13C NMR (100 MHz CDCl3) δ 136.0, 
134.4, 129.7, 127.7, 117.7, 84.8, 80.1, 78.2, 61.5, 38.3, 36.6, 35.5, 27.1, 26.5, 24.8, 19.4; 
HRMS (FAB) found 463.2281 [calcd for C26H36NaO4Si+ (M + H)+ 463.2275]. 
 




cyclopenta[d][1,3]dioxol-4-ol (23). To a stirred solution of 22 (7.5 g, 17.0 mmol) in 
anhydrous tetrahydrofuran (200 mL) was added tetra-n-butylammonium fluoride (1.0 M 
solution in tetrahydrofuran, 51.0 mL, 51.0 mmol) at 0 °C. The reaction mixture was stirred 
at room temperature for 16 h. The solvent was removed under reduced pressure and the 
residue was purified by column chromatography (methylene chloride:methanol = 9:1) to 
obtain 23 as colorless syrup (3.3 g, 93%):  –8.26 (c 0.121, CH3OH); 1H NMR (400 
MHz, CDCl3) δ 4.50 (t, J = 5.9 Hz, 1H), 4.36 (dd, J = 5.9, 2.4 Hz, 1H), 4.07 (m, 1H), 3.69 
(t, J = 6.1 Hz, 2H), 2.56 (br, 1H), 2.19 (m, 2H), 2.05 (br, 1H), 1.94 (dt, J = 13.2, 6.5 Hz, 
1H), 1.62 (dt, J = 13.2, 6.1 Hz , 1H), 1.55 (m, 2H), 1.51 (m, 3H), 1.35 (s, 3H); 13C NMR 
(100 MHz, CDCl3) δ 112.4, 85.1, 79.5, 70.6, 61.4, 38.8, 37.5, 35.2, 26.1, 24.1; HRMS (FAB) 
found 203.1274 [calcd for C10H19O4+ (M + H)+ 203.1278]. 
 








4H-cyclopenta[d][1,3]dioxol-4-ol (24). To a stirred solution of 23 (3.3 g, 16.3 mmol), 
triethylamine (6.8 mL, 48.9 mmol) and 4-N,N-dimethylaminopyridine (0.2 g, 1.6 mmol) in 
methylene chloride (40 mL) was added TBDPSCl (4.9 g, 17.9 mmol) at 0 °C, under 
nitrogen atmosphere. The reaction mixture was stirred for 2 h at room temperature, 
quenched with water (5 mL) and extracted with methylene chloride (2 × 40 mL). The 
organic portion was dried using anhydrous MgSO4 and concentrated in vacuo. The residue 
was purified by silica gel chromatography (hexanes:ethyl acetate = 4:1) to obtain 24 as 
colorless oil (5.7 g, 80%):  –20.4 (c 0.093, CH3OH); 1H NMR (400 MHz, CDCl3) δ 
7.69 (m, 4H), 7.42 (m, 6H), 4.43 (t, J = 5.6 Hz, 1H), 4.34 (dd, J = 1.2, 6 Hz, 1H), 4.02 (m, 
1H), 3.72 (m, 2H), 2.47 (d, J = 7.6 Hz, 1H), 2.19 (m, 1H), 1.87 (m, 1 H), 1.68 (m, 1 H), 
1.56 (m, 1 H), 1.51 (s, 3H), 1.46 (m, 1H), 1.34 (s, 3H), 1.08 (s, 9H); 13C NMR (100MHz, 
CDCl3) δ 135.7, 133.8, 129.7, 111.5, 85.1, 79.1, 71.3, 62.5; HRMS (FAB) found 441.2458 
[calcd for C26H36NaO4Si+ (M + H)+ 441.2456]. 
 









methylene chloride (50 mL) were added 4 Å  molecular sieves (1.04 g), 4-N-
methylmorpholine-N-oxide (0.55 g, 4.72 mmol) and tetra-n-propylammonium perruthenate 
(TPAP) (33 mg, 0.094 mmol) at room temperature. The reaction mixture was stirred at 
room temperature for 1 h and filtered through a pad of Celite and silica. The filtrates was 
concentrated to give a residue, which was purified by silica gel column chromatography 
(hexanes:ethyl acetate = 2.3:1) to obtain 13 as a colorless syrup (1.13 g, 99%):  –
84.1 (c 0.12, CH3OH); 1H NMR (400 MHz, CDCl3) δ 7.64 (m, 4H), 7.41 (m, 6H), 4.57 (d, 
J = 5.6 Hz, 1H), 4.17 (m, 1H), 3.72 (m, 3H), 2.73 (dd, J = 8.8, 18.4 Hz, 1H), 2.61 (m, 1H), 
2.03 (dt, J = 1.6, 17.6 Hz, 1H), 1.68 (m, 1H), 1.43 (s, 3H), 1.33 (s, 3H), 1.05 (s, 9H); 13C 
NMR (100 MHz, CDCl3) δ 214.4, 135.7, 133.5, 130.0, 127.9, 112.3, 82.2, 78.3, 61.7, 40.1, 
36.2, 34.0, 27.0, 25.1, 19.3; HRMS (FAB) found 456.2572 [calcd for C26H38NO4Si+ (M + 
NH4)+ 456.2565]. 
 
Preparation of 25 
 
(3aS,4R,5R,6R,6aR)-6-(2-((tert-Butyldiphenylsilyl)oxy)ethyl)-5-fluoro-2,2-
dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-ol (25). To a stirred solution of 13 
(6.4 g, 14.5 mmol) in anhydrous tetrahydrofuran (105 mL) at –78 °C, under nitrogen 
atmosphere were added chlorotrietylsilane (9.73 mL, 58.0 mmol) and lithium bis 
(trimethylsilyl)amide (1.0 M solution in tetrahydrofuran, 29.0 mL, 29.0 mmol). The 
reaction mixture was stirred at –78 °C for 1 h, warmed to 0 °C and quenched using saturated 





combined organic layers were dried using anhydrous MgSO4 and concentrated in vacuo to 
get the crude  silyl enol ether, which was used immediately for the next step without 
further purification. 
To a stirred solution of the crude silyl enol ether in anhydrous acetonitrile (120 mL) was 
added Selectfluor®  (7.7 g, 21.8 mmol) at 0 °C. The reaction mixture was stirred for 16 h at 
0 °C, diluted with brine (50 mL) and extracted with ethyl acetate (2 × 100) . The organic 
layers were dried using anhydrous MgSO4, filtered and concentrated in vacuo. The residue 
was purified by silica gel column chromatography (hexanes:ethyl acetate = 5.6:1) to obtain 
an inseparable mixture of the mono fluoroketone 11 and the mono fluoro geminal diol (3.7 
g, 84%). 
To a stirred solution of 11 (4.06 g, 8.89 mmol) in tetrahydrofuran (120 mL) was slowly 
added sodium borohydride (0.5 mg, 13.34 mmol) at –40 °C. The reaction mixture was 
stirred at –40 °C for 1 h and then warmed to 0 °C. The mixture was stirred at 0 °C for 3 h, 
diluted with water (50 mL) and extracted with ethyl acetate (2 × 100 mL). The organic 
layers were dried over anhydrous MgSO4, filtered and concentrated in vacuo. The residue 
was purified by silica gel chromatography (hexanes:ethyl acetate = 11.5:1) to obtain 25 as 
colorless oil (2.62 g, 64%);  –43.5 (c 0.14, CH3OH): 1H NMR (400 MHz, CDCl3) δ 
7.68 (m, 4H), 7.40 (m, 6H), 4.9 (ddd, J = 3.6, 4.4, 50.8 Hz, 1H), 4.64 (m, 1H), 4.54 (m, 
1H), 4.08 (m, 1H), 3.75 (m, 1H), 2.73 (dd, J = 2.8, 4.4 Hz, 1H), 2.48 (m, 1H), 1.89 (m, 1H), 
1.66 (m, 1H), 1.51 (s, 3H), 1.34 (s, 3H), 1.05 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 135.8, 
133.9, 129.8, 113.8, 101.6, 99.8, 84.0, 78.2, 72.3 (J = 27.5 Hz), 62.5, 43.5 (J = 72.0 Hz), 
29.6 (J = 5.9 Hz), 26.5, 24.7, 19.3; 19F NMR (376 MHz, CDCl3) δ –204.7; HRMS (FAB) 
found 459.2366 [calcd for C26H36FO4Si+ (M + H)+ 459.2361]. 
 








cyclopenta[d][1,3]dioxol-4-yl)ethoxy)(tert-butyl)diphenylsilane (27). To a stirred 
solution of 25 (2.35 g, 5.12 mmol) in anhydrous pyridine (50 mL) was added triflic 
anhydride (1.72 mL, 10.24 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 1 h, 
quenched with water (3 mL) and concentrated in vacuo. The residue was diluted with ethyl 
acetate (100 mL) and washed with 15% aqueous CuSO4 solution (3 × 30 mL). The organic 
portion was dried over anhydrous MgSO4, filtered and concentrated in vacuo to get the 
crude triflate, which was used immediately for the next step without further purification. 
To a stirred solution of the crude triflate in anhydrous N,N-dimethyl formamide (50 mL) 
was added sodium azide (3.08 g, 51.2 mmol) at room temperature. The reaction mixture 
was stirred at 100 °C for 12 h, cooled to room temperature and diluted with water (10 mL). 
The solution was extracted with diethyl ether (100 mL). The organic portion was washed 
with water (5 × 50 mL), dried using anhydrous MgSO4, filtered and concentrated in vacuo. 
The residue was purified by silica gel column chromatography (hexanes:ethyl acetate = 
32.3:1) to obtain 27 as colorless oil (0.36 g, 90%):  –98.7 (c 0.155, CH3OH); 1H 
NMR (400 MHz, CDCl3) δ 7.69 (m, 4H), 7.41 (m, 6H), 4.92 (dt, J = 3.2, 52.8 Hz, 1 H), 
4.68 (m, 1H), 4.45 (m, 1H), 3.79 (m, 2H), 3.67 (m, 1H), 2.34 (m, 1H), 1.87 (m, 1H), 1.52 
(s, 3H), 1.32 (s, 3H), 1.07 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 135.8, 133.8, 129.9, 
127.8, 114.2, 99.4, 97.6, 83.6, 82.3, 68.3 (J = 15.7 Hz), 61.9, 45.5 (J = 17.7 Hz), 30.3 (J = 
4.6 Hz), 27.4, 24.9, 19.3; 19F NMR (376 MHz, CDCl3) δ –205.5; HRMS (FAB) found 
506.2254 [calcd for C26H34FN3NaO3Si+ (M + Na)+ 506.2246]. 
 









diamine (29). To a stirred solution of 27 (0.991 g, 2.04 mmol) in methanol (50 mL) was 
added 10% palladium/carbon (wetted with ca. 55% water) (250 mg) at room temperature. 
The reaction mixture was stirred under H2 for 3 h. After completion of reaction (TLC), the 
suspension was filtered through a pad of Celite and concentrated to obtain the amine as 
colorless syrup, which was used for the next step without further purification.  
To a solution of the crude amine (0.933 g, 2.04 mmol) in n-butanol (20 mL) were added 5-
amino-4,6-dichloropyrimidine and N,N-diisopropylethylamine at room temperature. The 
reaction mixture was subjected to microwave irradiation at 170 °C for 10 h. After cooling 
to room temperature, the reaction mixture was concentrated in vacuo, diluted with ethyl 
acetate (30 mL), washed with saturated aqueous NaHCO3, dried over anhydrous MgSO4, 
filtered, and concentrated in vacuo. The residue was purified by silica gel chromatography 
(hexanes:ethyl acetate = 4.6:1) to obtain 27 as colorless oil (0.91 g, 76%):  –19.7  
(c 0.167, CHCl3); 1H NMR (500 MHz, CDCl3) δ 8.07 (s, 1H), 7.60–7.64 (m, 4H), 7.44–
7.34 (m, 6H), 5.33 (d, J = 7.9 Hz), 5.05 (dt, J = 3.0, 53.3 Hz, 1H), 4.75–4.64 (m, 1H), 4.61 
(merged dd, J1 = J2 = 6.7 Hz, 1H), 4.44 (merged dd, J1 = J2 = 6.7 Hz, 1H),  3.82–3.71 (m, 
2H), 3.60–3.45 (brs, 2 H), 2.51–2.37 (m, 1H), 1.94–1.80 (m, 2H), 1.54 (s, 3H), 1.30 (s, 3H), 
1.03 (s, 9H); 13C NMR (150 MHz, CDCl3) δ 154.3, 149.3, 143.2, 135.5, 133.6, 129.6, 127.6, 
122.3, 114.1, 98.3 (J = 211.8 Hz), 84.1, 83.4, 61.8, 60.3 (J = 19.4 Hz), 45.6 (J = 21.8 Hz), 
30.4 (J = 5.6), 27.3, 26.8, 24.9, 19.1 19F NMR (376 MHz, CDCl3) δ –208.0; HRMS (FAB) 










Dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)-6-chloro-9H-purine (31). To a 
stirred solution of 29 (0.91 g, 1.56 mmol) in diethoxymethyl acetate (15 mL) was heated at 
120 °C for 14 h. The reaction was cooled and the solvent was removed under reduced 
pressure. The residue was purified by silica gel chromatography (hexanes:ethyl acetate = 
9:1) to obtain 31 as a white foam (0.87 g, 93%):  –12.3 (c 0.162, CH3OH); UV 
(CH3OH) λmax 263 nm; 1H NMR (400 MHz, CDCl3) δ 8.78 (s, 1H), 8.32 (d, J = 2.4 Hz, 
1H), 7.68 (m, 4H), 7.4 (m, 6H), 5.18 (m, 1H), 5.08 (m, 2H), 4.62 (m, 1H), 3.81 (m, 2H), 
2.64 (m, 1H), 1.95 (m, 2H), 1.59 (s, 3H), 1.34 (s, 3H), 1.06 (s, 9H); 13C NMR (100 MHz, 
CDCl3) δ 152.3, 144.2, 135.7, 133.7, 129.9, 127.9, 115.3, 99.2, 97.4, 83.4, 83.0, 63.3, 61.7, 
46.0, 30.5, 27.6, 27.0, 25.1, 19.3; 19F NMR (376 MHz, CDCl3) δ –200.72; HRMS (FAB) 
found 595.2290 [calcd for C31H37ClFN4O3Si+ (M + H)+ 595.2302]. 
 








hydroxyethyl)cyclopentane-1,2-diol (33). To a stirred solution of 31 (0.57 g, 0.966 mmol) 
in methanol (3 mL) was added 50% aqueous trifluoroacetic acid (15 mL) at 0 °C. The 
reaction mixture was stirred at room temperature for 2 h. The solvent was removed under 
reduced pressure and the residue was purified by column chromatography (methylene 
chloride:methanol = 9:1) to obtain 33 (0.23 g, 75%), which was crystallized from diethyl 
ether/methanol: white solid; mp 147–149 °C;  –32.7 (c 0.107, CH3OH); UV 
(CH3OH) λmax 263.5 nm; 1H NMR (400 MHz, CD3OD) δ 8.75 (s, 1H), 8.71 (d, J = 2.4 Hz, 
1H), 5.18 (dt, J = 4.0, 51.6 Hz, 1H), 5.15, (m, 1H), 4.80 (m, 1H), 4.06 (t, 5.4 Hz, 1H), 3.72 
(m, 2H), 2.41 (m, 1H), 1.9 (m, 2H); 13C NMR (100 MHz, CD3OD) δ 154.0, 153.2, 151.4, 
147.4 (J = 3.62 Hz), 94.3, 92.5, 74.5, 73.7, 64.3 (J = 17.3 Hz), 31.8 (J = 7.1 Hz); 19F NMR 
(376 MHz, CD3OD) δ –204.34; HRMS (FAB) found 317.0810 [calcd for C12H12ClFN4O3+ 
(M + H)+ 317.0811]. 
 









33 (70 mg, 0.22 mmol) in saturated tert-butanolic ammonia was heated at 90 °C for 3 h. 
After cooling to room temperature, the solvent was removed under reduced pressure and 
the residue was purified by silica gel chromatography (methylene chloride:methanol = 5:1) 
to obtain 3 (44 mg, 68%), which was crystallized from diethyl ether/methanol: white solid; 
mp 168–170 °C;  –49.3 (c 0.146, CH3OH); UV (CH3OH) λmax 259 nm, 1H NMR 
(400 MHz, CD3OD) δ 8.26 (d, J = 2.0 Hz, 1H), 8.20 (s, 1H), 5.11 (dt, J = 3.6, 55.2 Hz, 1H), 
4.99 (ddd, J = 3.2, 9.6, 26.4 Hz, 1H), 4.75 (m, 1H), 4.04 (m, 1H), 3.71 (m, 2H), 2.38 (m, 
1H), 1.89 (m, 2H); 13C NMR (100 MHz, CD3OD) δ 157.4, 153.9, 151.5, 141.7 (J = 4.4 Hz), 
94.2, 92.6, 74.5, 73.7, 63.7 (J = 17.1 Hz), 61.1, 47.8, (J = 17.9 Hz), 31.8 (J = 6.6 Hz); 19F 
NMR (376 MHz, CD3OD) δ –204.9; HRMS (FAB) found 298.1310 [calcd for 
C12H17FN5O3+ (M + H)+ 298.1310]. 
 




yl)cyclopentane-1,2-diol (4). A steel pressure vessel containing a solution of 33 (55 mg, 
0.17 mmol) in methanol was added methylamine solution 40 wt.% in H2O. The reaction 
mixture was heated at 80 °C for 5 h. After cooling to room temperature, the solvent was 
removed under reduced pressure and the residue was purified by silica gel chromatography 
(methylene chloride:methanol = 5:1) to obtain 4 (37 mg, 68%), which was crystallized from 
diethyl ether/methanol: white solid; mp 171–173 °C;  –1.06 (c 0.160, CH3OH); UV 





1H), 5.09 (dt, J = 3.6, 54.8 Hz, 1H), 4.96 (ddd, J = 3.0, 9.4, 26.7 Hz, 1H), 4.74 (t, J = 7.4 
Hz, 1H), 4.02 (t, J = 6.0 Hz, 1H), 3.74–3.67 (m, 2H), 3.20–3.00 (brs, 3H), 2.42–2.31 (m, 
1H), 1.94–1.84 (m, 2H); 13C NMR (125 MHz, CD3OD) δ 157.5, 154.6, 151.1, 141.8 (J = 
3.6 Hz), 121.1, 94.2 (J = 180.5 Hz), 75.3, 74.4, 64.4 (J = 17.0 Hz), 61.8, 48.5 (J = 18.5 Hz), 
32.6 (J = 6.6 Hz), 28.6; 19F NMR (376 MHz, CD3OD) δ –206.4; HRMS (FAB) found 
312.1460 [calcd for C13H19FN5O3+ (M + H)+ 312.1466]. 
 




dihydro-6H-purin-6-one (5). To a stirred solution of 33 (50 mg, 0.158 mmol) in 1,4-
dioxane (3 mL) was added 1 N HCl (3 mL) at room temperature. The reaction mixture was 
heated at reflux overnight, cooled to room temperature and concentrated in vacuo. The 
residue was purified by C-18 reverse-phase silica gel column chromatography (H2O) to 
give 5 (33 mg, 70%), which was crystallized from diethyl ether/methanol: white solid; mp 
184–186 °C;  –33.25 (c 0.160, H2O); UV (H2O) λmax 250 nm; 1H NMR (800 MHz, 
D2O) δ 8.20 (s, 1H), 8.08 (s, 1H), 5.07 (dt, J = 3.7, 54.2 Hz, 1H), 4.91 (ddd, J = 3.2, 9.8, 
30.2 Hz, 1H), 4.74-4.72 (m, 1H), 4.05 (t, J = 5.9 Hz, 1H), 3.65 (t, J = 6.6 Hz, 2H), 2.33-
2.25 (m, 1H), 1.87-1.77 (m, 2H); 13C NMR (150 MHz, D2O) δ 158.4, 149.4, 145.7, 141.0, 
123.0, 91.9 (J = 179.9 Hz), 72.5, 72.1, 61.8 (J = 16.9 Hz), 59.6, 45.5 (J = 18.5 Hz), 29.4 (J 
= 6.9 Hz) ); 19F NMR (376 MHz, CD3OD) δ -204.9; HRMS (FAB) found 299.1150 [calcd 










methoxyacrylamide (35). To a stirred solution of 27 (0.2 g, 0.41 mmol) in methanol (15 
mL) was added Pd/C (10%, 50 mg) at room temperature. The reaction mixture was stirred 
under H2 for 3 h. The suspension was filtered through Celite and concentrated in vacuo to 
obtain the crude amine as colorless syrup, which was used for the next step without further 
purification. To a stirred solution of the crude amine in N,N-dimethylformamide (4 mL) 
was added solution of isocyanate compound 39 (0.1 g, 0.82 mmol) in anhydrous benzene 
(3 mL) at –20 °C over 4 Å  molecular sieves under N2 atmosphere. The reaction mixture 
was warmed to room temperature and stirred overnight. The mixture was filtered and 
concentrated in vacuo (co-evaporation with toluene and ethanol), maintaining the 
temperature below 40 °C. The residue was purified by silica gel chromatography 
(hexanes:ethyl acetate = 3:2) to obtain 40 (0.2 g, 85%): yellow syrup;  +11.03 (c 
0.330, CHCl3); 1H NMR (500 MHz, CDCl3) δ 9.97 (s, 1H), 9.19 (d, J = 8.25, 1H), 7.69–
7.66 (m, 5H), 7.43–7.36 (m, 6H), 5.40 (d, J = 12.3 Hz, 1H), 4.90 (dt, J = 3.0, 53.1 Hz, 1H), 
4.57 (t, J = 6.3 Hz, 1H), 4.44–4.38 (m, 2H), 3.81–3.71 (m, 2H), 3.69 (s, 3H), 2.40–2.32 (m, 
1H), 1.90–1.83 (m, 2H), 1.49 (s, 3H), 1.29 (s, 3H), 1.04 (s, 9H); 13C NMR (125 MHz, 
CDCl3) δ 168.0, 163.6, 155.3, 135.5, 133.7, 129.6, 127.6, 113.7, 98.5 (J = 178.4 Hz), 97.6, 





24.9, 19.1; 19F NMR (376 MHz, CDCl3) δ –206.7; HRMS (FAB) found 585.2780 [calcd 
for C31H42FN2O6Si+ (M + H)+ 585.2791]. 
 




hydroxyethyl)cyclopentyl)pyrimidine-2,4(1H,3H)-dione (6). To a stirred solution of 40 
(0.16 g, 0.28 mmol) in 1,4-dioxane (3 mL) was added 2 M sulfuric acid (2 mL) at room 
temperature. The reaction mixture was heated at reflux for 30 min, cooled to room 
temperature and concentrated in vacuo. The residue was diluted with methanol (10 mL), 
neutralized by weak basic resin (DOWEX®  66 ion-exchange resin), filtered and 
concentrated in vacuo to get the crude uracil, which was purified by silica gel 
chromatography (methylene chloride:methanol = 9:1) to give 6 (43 mg, 56%) and 
crystallized from diethyl ether/methanol: white solid; mp 87–89 °C; [α]D
25 -99.5 (c 0.150, 
CH3OH); UV (H2O) λmax 253 nm; 1H NMR (500 MHz, CD3OD) δ 7.68 (d, J = 8.0 Hz, 1H), 
5.69 (d, J = 8.1 Hz, 1H), 4.99 (dt, J = 3.6, 55.4 Hz, 1H), 4.88 (ddd, J =3.3, 9.8, 30.7, 1H), 
4.45 (merged dd, J1 = J2 = 7.1, 1H), 3.91 (t, J = 5.9 Hz, 1H), 3.71–3.64 (m, 2H), 2.29–2.20 
(m, 1H), 1.88–1.75 (m, 2H); 13C NMR (125 MHz, CD3OD) δ 167.0, 154.1, 145.6 (J = 3.9 
Hz), 102.7, 94.3 (J = 180.0 Hz) 75.1, 72.4, 64.8 (J = 16.4 Hz), 61.8, 48.0 (J = 18.4 Hz), 
32.4 (J = 7.4 Hz); 19F NMR (376 MHz, CD3OD) δ –209.0; HRMS (FAB) found 275.1030 










dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-ol (26).  
To a stirred solution of 11 (5.7 g, 10.03 mmol) in anhydrous tetrahydrofuran (100 mL) at 
0 °C, under N2 atmosphere were added triethylamine (7.0 mL, 50.15 mmol), 
chlorotriethylsilane (8.4 mL, 50.15 mmol) and lithium bis trimethylsilyl amide (1.0 M 
solution in tetrahydrofuran, 25.1 mL, 25.08 mmol). The reaction mixture was stirred at 
room temperature for 1 h, warmed to 0 °C and quenched using saturated aqueous 
ammonium chloride solution. The solution was extracted with ethyl acetate (2 × 100 mL). 
The combined organic portions were dried using MgSO4 and concentrated in vacuo to 
obtain the crude silyl enol ether, which was used immediately for the next step without 
further purification. 
To a stirred solution of the crude silyl enol ether in anhydrous acetonitrile (100 mL) was 
added a solution of Selectfluor
®
 (7.11 g, 20.06 mmol) in acetonitrile (85 mL) at 0 °C. The 
reaction mixture was stirred overnight at room temperature, concentrated in vacuo and 
diluted with ethyl acetate (2 × 100 mL). The combined organic portions was dried using 
MgSO4 and concentrated in vacuo. The residue was purified by silica gel column 
chromatography (hexanes:ethyl acetate = 2.3:1) to obtain 12 as the difluoro geminal diol 
(2.37 g, 50%). 
To a stirred solution of 12 (2.19 g, 4.61 mmol) in tetrahydrofuran (45 mL) was added 
sodium borohydride (0.21 g, 5.53 mmol) at 0 °C, over a period of 15 min. The reaction 
mixture was stirred at 0 °C for 3 h, diluted with water (30 mL) and few drops of acetic acid 





dried over anhydrous MgSO4 and concentrated in vacuo. The residue was purified by silica 
gel column chromatography (hexanes:ethyl acetate = 9:1) to obtain 26 as colorless oil (1.79 
g, 81%): [α]D
20 +18.8 (c 0.340, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.69–7.66 (m, 4H), 
7.44–7.36 (m, 6H), 4.54 (m, 1H), 4.36–4.34 (m, 1H), 3.97 (ddd, J = 6.4, 12.5 Hz, 1H), 
3.79–3.74 (m, 2H), 2.87 (d, J = 5.6 Hz, 1H), 2.65–2.60 (m, 1H), 1.97–1.91 (m, 1H), 1.58–
1.52 (m, 4H), 1.32 (s, 3H), 1.05 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 135.6, 133.5, 129.6, 
128.0 (J = 248.8, 263.5 Hz), 127.6, 112.9, 81.1, 75.2, 71.0 (J = 12.4, 19.8 Hz), 61.5, 44.9 
(J = 20.5 Hz), 28.8, 26.8, 26.0, 24.4, 19.1; 19F NMR (CDCl3, 376 MHz) δ –112.7 (dd, J = 
16.1, 241.9 Hz), –115.8 (dd, J = 24.8, 242.7 Hz); HRMS (FAB) found 494.2540 [calcd for 
C26H38F2NO4Si+ (M + NH4)+ 494.2533]. 
 




cyclopenta[d][1,3]dioxol-4-yl)ethoxy)(tert-butyl)diphenylsilane (28). To a stirred 
solution of 26 (1.65 g, 3.46 mmol) in anhydrous pyridine (30 mL) was added triflic 
anhydride (1.16 mL 6.92 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 1 h, 
quenched using saturated aqueous sodium bicarbonate solution (5 mL), concentrated in 
vacuo to get the crude compound, which was diluted with ethyl acetate (40 mL), washed 
with 15% aqueous CuSO4 solution and extracted with ethyl acetate (2 × 30 mL). The 





residue was purified by silica gel column chromatography (hexanes:ethyl acetate = 2.5:1) 
to obtain the triflate compound, which was used immediately for the next step. 
To a stirred solution of the triflate in anhydrous N,N-dimethylformamide (30 mL) was 
added sodium azide (0.62 g, 10.38 mmol) at room temperature. The reaction mixture was 
stirred at 60 °C for 12 h, cooled to room temperature and diluted with water (10 mL). The 
solution was extracted with diethyl ether (2 × 40 mL) . The organic layers were washed 
with water (5 × 30 mL), dried using anhydrous MgSO4 and concentrated in vacuo. The 
residue was purified by silica gel column chromatography (hexanes:ethyl acetate = 19:1) 
to obtain 28 as colorless oil (1.12 g, 64%): [α]20D +14.6 (c 0.335, CHCl3); 1H NMR (500 
MHz, CDCl3) δ 7.69–7.67 (m, 4H), 7.44–7.36 (m, 6H), 4.40–4.38 (m, 1H), 4.30–4.27 (m, 
1H), 3.94 (dt, J = 5.3, 17.6 Hz, 1H), 3.77 (t, J = 6.2 Hz, 2H), 2.66–2.59 (m, 1H), 2.02–1.96 
(m, 1H), 1.75–1.68 (m, 1H), 1.52 (s, 3H), 1.28 (s, 3H), 1.04 (s, 9H); 13C NMR (125 MHz, 
CDCl3) δ 135.6, 133.5, 129.6, 127.6, 127.3(J = 270.0, 275.0 Hz), 113.5, 80.1 (J = 8.6 Hz), 
79.5 (J = 7.0 Hz), 68.6 (J = 18.9, 22.8 Hz), 60.9, 46.5 (J = 20.1 Hz), 28.7 (J = 4.3 Hz), 29.0, 
26.8, 24.7, 19.2; 19F NMR (376 MHz, CDCl3) δ –104.5, –120.2; HRMS (FAB) found 
524.2161 [calcd for C26H33F2N3NaO3Si+ (M + Na)+ 524.2151]. 
 








dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)-6-chloro-9H-purine (32). To 
solution of 28 (0.93 g, 1.85 mmol) in methanol (18 mL) was added 10% palladium/carbon 
(wetted with ca. 55% water) (200 mg) at room temperature and the reaction mixture was 
exchanged with H2 gas for three times and stirred under H2 atmosphere at rt overnight. The 
suspension was filtered through Celite and concentrated to obtain the amine as colorless 
syrup which was used for the next step without further purification. 
To a stirred solution of the crude amine in 1,4-dioxane (15 mL) were added 4,6-dichloro-
5-formamidopyrimidine (0.71 g, 3.70 mmol) and triethylamine (1.9 mL, 13.60 mmol). The 
reaction mixture was heated at reflux for 2 d, cooled and the solvent was removed under 
reduced pressure and the residue was used for the next step without further purification. To 
the crude pyrimidine was added diethoxymethyl acetate (15 mL) and the reaction mixture 
was stirred at 120 °C overnight. The solvent was removed under reduced pressure and the 
residue was purified by silica gel column chromatography (hexane:ethyl acetate = 5:1) to 
obtain 32 (0.35 g, 30%) as a white foam: [α]D
20 –10.1 (c 0.250, CHCl3); 1H NMR (600 
MHz, CDCl3) δ 8.78 (s, 1H), 8.24 (d, J = 1.9 Hz, 1H), 7.70–7.67 (m, 4H), 7.43–7.36 (m, 
6H), 5.38–5.32 (m, 1H), 5.14 (t, J = 6.9 Hz, 1H), 4.52 (t, J = 6.4 Hz, 1H), 3.85–3.80 (m, 
2H), 2.98–2.90 (m, 1H), 2.09–2.03 (m, 1H), 1.86–1.81 (m, 1H), 1.59 (s, 3H), 1.31 (s, 3H), 





133.4, 131.4, 129.7, 127.7, 126.1(J = 247.5, 262.5 Hz), 114.5, 79.9 (J = 10.1 Hz), 78.8 (J 
= 7.2 Hz), 63.8 (J = 22.3 Hz), 60.6, 46.6 (J = 20.1 Hz), 28.6 (J = 4.3 Hz), 27.2, 26.8, 24.9, 
19.2; 19F NMR (376 MHz, CDCl3) δ –107.7, –117.1; HRMS (FAB) found 613.2213 [calcd 
for C31H36ClF2N4O3Si+ (M + H)+ 613.2208]. 
 




4H-cyclopenta[d][1,3]dioxol-4-yl)ethan-1-ol (34). To a stirred solution of 32 (0.28 g, 0.45 
mmol) in 1,4-dioxane (4 mL) was added 70% aqueous trifluoroacetic acid solution (12 mL) 
at 0 °C. The reaction mixture was stirred at room temperature for 2 h. The mixture was 
concentrated in vacuo and the residue was purified by silica gel column chromatography 
(methylene chloride:methanol = 9:1) to obtain 34 (0.12 g, 81 %), which was crystallized 
from diethyl ether/methanol: white solid; mp 80-82 °C [α]D
25 +53.2 (c 0.130, CH3OH); 
UV (CH3OH) λmax 264 nm; 1H NMR (500 MHz, CD3OD) δ 8.77 (s, 1H), 8.76 (d, J = 1.9 
Hz, 1H), 5.45 (ddd, J1 = J2 = 8.7 Hz, J3 = 17.9 Hz, 1H), 4.91–4.88 (m, 1H), 4.10–4.09 (m, 
1H), 3.74–3.69 (m, 2H), 2.70–2.67 (m, 1H), 2.01–1.95 (m, 1H), 1.83, 1.78 (m, 1H); 13C 
NMR (125 MHz, CDCl3) δ 155.0, 154.13, 152.42, 148.46, 133.03, 126.16 (J = 251.0, 259.1 
Hz), 74.3 (J = 7.1 Hz), 72.8 (J = 6.6 Hz), 65.9 (J = 23.0 Hz), 61.2, 31.3 (J = 6.8 Hz), 61.2, 





103.3, –115.9; HRMS (FAB) found 335.0713 [calcd for C12H14ClF2N4O3+ (M + H)+ 
335.0717]. 
 




4H-cyclopenta[d][1,3]dioxol-4-yl)ethan-1-ol (7). A steel pressure vessel containing a 
solution of 34 (33 mg g, 0.099 mmol) in saturated methanolic ammonia (20 mL) was heated 
at 70 °C overnight. After cooling to room temperature, the solvent was removed under 
reduced pressure and the residue was purified by silica gel column chromatography 
(methylene chloride:methanol = 9:1) to obtain 7 (0.012 g, 55% based on recovered starting 
material), which was crystallized from diethyl ether/methanol: white solid; mp 109–111 °C; 
[α]D
20 +131.8 (c 0.040, CH3OH); UV (CH3OH) λmax 261 nm; 1H NMR (500 MHz, CD3OD) 
δ 8.27 (d, J = 1.8 Hz, 1H), 8.20 (s, 1H), 5.29 (ddd, J1 = J2 = 8.4 Hz, J3 = 17.8 Hz, 1H), 4.77 
(dd, J =6.6, 8.8 Hz, 1H), 4.07 (t, J = 4.8 Hz, 1H), 3.74–3.69 (m, 2H), 2.69–2.62 (m, 1H), 
2.00–1.94 (m, 1H), 1.83–1.78 (m, 1H); 13C NMR (125 MHz, CDCl3) δ 158.2, 154.8, 152.6, 
142.7, 126.1 (J = 251.3, 258.5 Hz), 120.6, 74.0 (J = 7.9 Hz), 73.0 (J = 6.5 Hz), 65.2 (J = 
21.6 Hz), 61.3, 50.7, 31.3 (J = 6.5 Hz); 19F NMR (376 MHz, CD3OD) δ –103.3, –115.9; 










yl)tetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)ethan-1-ol (4). A steel pressure vessel 
containing a solution of 34 (10 mg, 0.03 mmol) in methanol (2 mL) was added 40% 
methylamine aqueous solution (0.25 mL, 3.22 mmol). The reaction mixture was heated at 
50 °C for 5 h. After cooling to room temperature, the solvent was removed under reduced 
pressure and the residue was purified by silica gel column chromatography (methylene 
chloride:methanol = 9:1) to obtain 4 (0.008 g, 81%), which was crystallized from diethyl 
ether/methanol; white solid; mp 89-91 °C; [α]D
20 +2.0 (c 0.160, CH3OH); UV (CH3OH) 
λmax 265 nm; 1H NMR (500 MHz, CD3OD) δ 8.25 (s, 1H), 8.21 (s, 1H), 5.27 (ddd, J1 = J2 
= 8.4, 17.8 Hz, 1H), 4.76 (dd, J = 6.6, 8.7 Hz, 1H), 4.06 (t, J =4.7 Hz, 1H), 3.74–3.68 (m, 
2H), 3.11 (brs, 3H), 2.66–2.61 (m, 1H), 2.00–1.94 (m, 1H), 1.83–1.77 (m, 1H); 13C NMR 
(125 MHz, CDCl3) δ 157.6, 154.8, 151.5, 142.0, 126.1 (J = 250.1, 258.38 Hz), 121.2, 74.2 
(J = 7.5 Hz), 73.0 (J = 7.0 Hz), 65.1 (J = 21.4 Hz), 61.3, 50.7, 31.3 (J = 6.5 Hz), 28.6; 19F 
NMR (376 MHz, CD3OD) δ –103.3, –115.9; HRMS (FAB) found 330.1386 [calcd for 
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VI. 1H and 13C NMR Copies 
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